From the Cover: Three-Dimensional (3D) HepaRG Spheroid Model With Physiologically Relevant Xenobiotic Metabolism Competence and Hepatocyte Functionality for Liver Toxicity Screening

Effective prediction of human responses to chemical and drug exposure is of critical importance in environmental toxicology research and drug development. While significant progress has been made to address this challenge using invitro liver models, these approaches often fail due to inadequate tissue model functionality. Herein, we describe the development, optimization, and characterization of a novel three-dimensional (3D) spheroid model using differentiated HepaRG cells that achieve and maintain physiologically relevant levels of xenobiotic metabolism (CYP1A2, CYP2B6, and CYP3A4/5). This invitro model maintains a stable phenotype over multiple weeks in both 96- and 384-well formats, supports highly reproducible tissue-like architectures and models pharmacologically- and environmentally important hepatic receptor pathways (ie AhR, CAR, and PXR) analogous to primary human hepatocyte cultures. HepaRG spheroid cultures use 50-100× fewer cells than conventional two dimensional cultures, and enable the identification of metabolically activated toxicants. Spheroid size, time in culture and culture media composition were important factors affecting basal levels of xenobiotic metabolism and liver enzyme inducibility with activators of hepatic receptors AhR, CAR and PXR. Repeated exposure studies showed higher sensitivity than traditional 2D cultures in identifying compounds that cause liver injury and metabolism-dependent toxicity. This platform combines the well-documented impact of 3D culture configuration for improved tissue functionality and longevity with the requisite throughput and repeatability needed for year-over-year toxicology screening.

[1]  E. Gallagher,et al.  The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4. , 1996, Toxicology and applied pharmacology.

[2]  Gerd A. Kullak-Ublick,et al.  Expression of the hepatocyte canalicular multidrug resistance protein (MRP2) in primary biliary cirrhosis. , 2002, Hepatology research : the official journal of the Japan Society of Hepatology.

[3]  F. Stockdale,et al.  Cell-cell interactions promote mammary epithelial cell differentiation , 1985, The Journal of cell biology.

[4]  T. Andersson,et al.  In Vitro Evaluation of Major In Vivo Drug Metabolic Pathways Using Primary Human Hepatocytes and HepaRG Cells in Suspension and a Dynamic Three-Dimensional Bioreactor System , 2012, Journal of Pharmacology and Experimental Therapeutics.

[5]  A. Callendrello,et al.  Evaluation of Calibration Curve–Based Approaches to Predict Clinical Inducers and Noninducers of CYP3A4 with Plated Human Hepatocytes , 2014, Drug Metabolism and Disposition.

[6]  A. Müsch,et al.  Hepatocyte polarity. , 2013, Comprehensive Physiology.

[7]  C. Wild,et al.  The toxicology of aflatoxins as a basis for public health decisions. , 2002, Mutagenesis.

[8]  M. Uchida The metabolism of Cyclosporin A. , 1994 .

[9]  P. Lurie,et al.  Case series of liver failure associated with rosiglitazone and pioglitazone , 2009, Pharmacoepidemiology and drug safety.

[10]  G. Cooper The Cell: A Molecular Approach , 1996 .

[11]  M. Yarmush,et al.  A microfluidic hepatic coculture platform for cell-based drug metabolism studies. , 2010, Biochemical pharmacology.

[12]  T. Andersson,et al.  Cytochrome P450-Dependent Metabolism in HepaRG Cells Cultured in a Dynamic Three-Dimensional Bioreactor , 2011, Drug Metabolism and Disposition.

[13]  A. Parkinson An Overview of Current Cytochrome P450 Technology for Assessing the Safety and Efficacy of New Materials , 1996, Toxicologic pathology.

[14]  Sally Robinson,et al.  Reducing attrition in drug development: smart loading preclinical safety assessment. , 2014, Drug discovery today.

[15]  Albert P. Li,et al.  Metabolism Comparative Cytotoxicity Assay (MCCA) and Cytotoxic Metabolic Pathway Identification Assay (CMPIA) with cryopreserved human hepatocytes for the evaluation of metabolism-based cytotoxicity in vitro: proof-of-concept study with aflatoxin B1. , 2009, Chemico-biological interactions.

[16]  Jonathan P. Jackson,et al.  Contextualizing Hepatocyte Functionality of Cryopreserved HepaRG Cell Cultures , 2016, Drug Metabolism and Disposition.

[17]  B. Drénou,et al.  Transdifferentiation of hepatocyte‐like cells from the human hepatoma HepaRG cell line through bipotent progenitor , 2007, Hepatology.

[18]  Yaakov Nahmias,et al.  Long-term culture and expansion of primary human hepatocytes , 2015, Nature Biotechnology.

[19]  Leming Shi,et al.  Similarities and Differences in the Expression of Drug-Metabolizing Enzymes between Human Hepatic Cell Lines and Primary Human Hepatocytes , 2011, Drug Metabolism And Disposition.

[20]  N. Wong,et al.  A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping , 2000, Hepatology.

[21]  Peter V. Henstock,et al.  Cellular imaging predictions of clinical drug-induced liver injury. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  C. Alves,et al.  Number needed to harm in the post‐marketing safety evaluation: results for rosiglitazone and pioglitazone , 2015, Pharmacoepidemiology and drug safety.

[23]  André Guillouzo,et al.  EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS , 2006, Drug Metabolism and Disposition.

[24]  Weida Tong,et al.  FDA-approved drug labeling for the study of drug-induced liver injury. , 2011, Drug discovery today.

[25]  Wen Xie,et al.  Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: A case study with phenobarbital as a model constitutive androstane receptor (CAR) activator , 2014, Critical reviews in toxicology.

[26]  André Guillouzo,et al.  The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. , 2007, Chemico-biological interactions.

[27]  P. Ganey,et al.  Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[28]  HighWire Press,et al.  Drug metabolism and disposition : the biological fate of chemicals. , 1973 .

[29]  D. Fish,et al.  The safety profile of the fluoroquinolones. , 2000, Clinical therapeutics.

[30]  R. Obach,et al.  Validated assays for human cytochrome P450 activities. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[31]  B. K. Park,et al.  Quantification of Drug-Induced Inhibition of Canalicular Cholyl-l-Lysyl-Fluorescein Excretion From Hepatocytes by High Content Cell Imaging. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[32]  T. Singer,et al.  Bioprinted 3D Primary Liver Tissues Allow Assessment of Organ-Level Response to Clinical Drug Induced Toxicity In Vitro , 2016, PloS one.

[33]  X. Chu,et al.  Comparison of Immortalized Fa2N-4 Cells and Human Hepatocytes as in Vitro Models for Cytochrome P450 Induction , 2008, Drug Metabolism and Disposition.

[34]  N. Renaud,et al.  Is 1-Aminobenzotriazole an Appropriate in Vitro Tool as a Nonspecific Cytochrome P450 Inactivator? , 2009, Drug Metabolism and Disposition.

[35]  Amish Asthana,et al.  Microtissue size and hypoxia in HTS with 3D cultures. , 2012, Drug discovery today.

[36]  M. Ingelman-Sundberg,et al.  Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[37]  R. Chamuleau,et al.  Liver Progenitor Cell Line HepaRG Differentiated in a Bioartificial Liver Effectively Supplies Liver Support to Rats with Acute Liver Failure , 2012, PloS one.

[38]  B. Stieger,et al.  Hepatic Transport Mechanisms of Cholyl-l-Lysyl-Fluorescein , 2010, Journal of Pharmacology and Experimental Therapeutics.

[39]  Kenneth M. Yamada,et al.  Modeling Tissue Morphogenesis and Cancer in 3D , 2007, Cell.

[40]  Sandra Coecke,et al.  Three-dimensional HepaRG model as an attractive tool for toxicity testing. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[41]  B. Herpers,et al.  A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies , 2014, Archives of Toxicology.

[42]  M. Ingelman-Sundberg,et al.  Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease , 2016, Scientific Reports.

[43]  Y. Lai,et al.  Absolute Difference of Hepatobiliary Transporter Multidrug Resistance-Associated Protein (MRP2/Mrp2) in Liver Tissues and Isolated Hepatocytes from Rat, Dog, Monkey, and Human , 2009, Drug Metabolism and Disposition.

[44]  G. Ubeaud‐Séquier,et al.  Implication of hepatic transporters (MDR1 and MRP2) in inflammation‐associated idiosyncratic drug‐induced hepatotoxicity investigated by microvolume cytometry , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[45]  Elmar Heinzle,et al.  3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[46]  E. Gale Lessons from the glitazones: a story of drug development , 2001, The Lancet.

[47]  F. Noor,et al.  3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies. , 2014, Toxicology in vitro : an international journal published in association with BIBRA.

[48]  Hwan-Goo Kang,et al.  Chemically induced hepatotoxicity in human stem cell-induced hepatocytes compared with primary hepatocytes and HepG2 , 2016, Cell Biology and Toxicology.

[49]  HighWire Press,et al.  The journal of pharmacology and experimental therapeutics , 1909 .

[50]  Vikram Sinha,et al.  In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America Perspective , 2009, Drug Metabolism and Disposition.

[51]  J. Bauman,et al.  Reaction phenotyping in drug discovery: moving forward with confidence? , 2003, Current drug metabolism.

[52]  J. Boyer,et al.  Drug‐induced cholestasis , 2011, Hepatology.

[53]  J. Derancourt,et al.  Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[54]  Yvonne Will,et al.  Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[55]  Christian Trepo,et al.  Infection of a human hepatoma cell line by hepatitis B virus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[56]  P. Ganey,et al.  Trovafloxacin-induced replication stress sensitizes HepG2 cells to tumor necrosis factor-alpha-induced cytotoxicity mediated by extracellular signal-regulated kinase and ataxia telangiectasia and Rad3-related. , 2015, Toxicology.

[57]  M. Schwab,et al.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, Pharmacology & therapeutics.

[58]  H. Yamazaki,et al.  Functional polymer‐dependent 3D culture accelerates the differentiation of HepaRG cells into mature hepatocytes , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[59]  William M. Lee,et al.  Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States , 2002, Annals of Internal Medicine.